Treatment of small cell lung cancer

Anupama Kurup, Nasser H. Hanna

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

The incidence of small cell lung cancer (SCLC) is declining in the United States (US). SCLC is nearly universally smoking-related and is very sensitive to both chemotherapy and radiation therapy. In contrast to non-small cell lung cancer (NSCLC), SCLC is staged as either limited-stage disease (LD) or extensive-stage disease (ED). Chemotherapy remains the essential component for treatment of all patients with SCLC, regardless of stage or performance status. In LD, the addition of radiation therapy improves survival over chemotherapy alone. However, the dose, timing and schedule of radiation are not well defined. Prophylactic cranial irradiation (PCI) reduces brain relapse rates, and modestly improves survival in patients in a clinical remission. Many chemotherapy agents and combinations result in high response rates in ED SCLC; however, median survival time remains 8-10 months. Cisplatin (or carboplatin) and etoposide is the standard doublet used in the United States. One study has shown cisplatin plus irinotecan to have a survival benefit over cisplatin plus etoposide, but confirmatory studies are needed. Patients with ED frequently relapse, and relapsed/refractory SCLC has a poor prognosis. The challenge remains to identify novel therapies and molecular targets to improve survival in SCLC.

Original languageEnglish (US)
Pages (from-to)117-126
Number of pages10
JournalCritical Reviews in Oncology/Hematology
Volume52
Issue number2
DOIs
StatePublished - Nov 1 2004

Fingerprint

Small Cell Lung Carcinoma
Survival
Cisplatin
irinotecan
Etoposide
Drug Therapy
Therapeutics
Radiotherapy
Cranial Irradiation
Recurrence
Carboplatin
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Appointments and Schedules
Smoking
Radiation
Incidence
Brain

Keywords

  • Carboplatin
  • Chemoradiation
  • Cisplatin
  • Etoposide
  • Prophylactic cranial irradiation
  • Small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Treatment of small cell lung cancer. / Kurup, Anupama; Hanna, Nasser H.

In: Critical Reviews in Oncology/Hematology, Vol. 52, No. 2, 01.11.2004, p. 117-126.

Research output: Contribution to journalReview article

@article{e776033a22eb4f78a95537ce5e15661c,
title = "Treatment of small cell lung cancer",
abstract = "The incidence of small cell lung cancer (SCLC) is declining in the United States (US). SCLC is nearly universally smoking-related and is very sensitive to both chemotherapy and radiation therapy. In contrast to non-small cell lung cancer (NSCLC), SCLC is staged as either limited-stage disease (LD) or extensive-stage disease (ED). Chemotherapy remains the essential component for treatment of all patients with SCLC, regardless of stage or performance status. In LD, the addition of radiation therapy improves survival over chemotherapy alone. However, the dose, timing and schedule of radiation are not well defined. Prophylactic cranial irradiation (PCI) reduces brain relapse rates, and modestly improves survival in patients in a clinical remission. Many chemotherapy agents and combinations result in high response rates in ED SCLC; however, median survival time remains 8-10 months. Cisplatin (or carboplatin) and etoposide is the standard doublet used in the United States. One study has shown cisplatin plus irinotecan to have a survival benefit over cisplatin plus etoposide, but confirmatory studies are needed. Patients with ED frequently relapse, and relapsed/refractory SCLC has a poor prognosis. The challenge remains to identify novel therapies and molecular targets to improve survival in SCLC.",
keywords = "Carboplatin, Chemoradiation, Cisplatin, Etoposide, Prophylactic cranial irradiation, Small cell lung cancer",
author = "Anupama Kurup and Hanna, {Nasser H.}",
year = "2004",
month = "11",
day = "1",
doi = "10.1016/j.critrevonc.2004.08.005",
language = "English (US)",
volume = "52",
pages = "117--126",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Treatment of small cell lung cancer

AU - Kurup, Anupama

AU - Hanna, Nasser H.

PY - 2004/11/1

Y1 - 2004/11/1

N2 - The incidence of small cell lung cancer (SCLC) is declining in the United States (US). SCLC is nearly universally smoking-related and is very sensitive to both chemotherapy and radiation therapy. In contrast to non-small cell lung cancer (NSCLC), SCLC is staged as either limited-stage disease (LD) or extensive-stage disease (ED). Chemotherapy remains the essential component for treatment of all patients with SCLC, regardless of stage or performance status. In LD, the addition of radiation therapy improves survival over chemotherapy alone. However, the dose, timing and schedule of radiation are not well defined. Prophylactic cranial irradiation (PCI) reduces brain relapse rates, and modestly improves survival in patients in a clinical remission. Many chemotherapy agents and combinations result in high response rates in ED SCLC; however, median survival time remains 8-10 months. Cisplatin (or carboplatin) and etoposide is the standard doublet used in the United States. One study has shown cisplatin plus irinotecan to have a survival benefit over cisplatin plus etoposide, but confirmatory studies are needed. Patients with ED frequently relapse, and relapsed/refractory SCLC has a poor prognosis. The challenge remains to identify novel therapies and molecular targets to improve survival in SCLC.

AB - The incidence of small cell lung cancer (SCLC) is declining in the United States (US). SCLC is nearly universally smoking-related and is very sensitive to both chemotherapy and radiation therapy. In contrast to non-small cell lung cancer (NSCLC), SCLC is staged as either limited-stage disease (LD) or extensive-stage disease (ED). Chemotherapy remains the essential component for treatment of all patients with SCLC, regardless of stage or performance status. In LD, the addition of radiation therapy improves survival over chemotherapy alone. However, the dose, timing and schedule of radiation are not well defined. Prophylactic cranial irradiation (PCI) reduces brain relapse rates, and modestly improves survival in patients in a clinical remission. Many chemotherapy agents and combinations result in high response rates in ED SCLC; however, median survival time remains 8-10 months. Cisplatin (or carboplatin) and etoposide is the standard doublet used in the United States. One study has shown cisplatin plus irinotecan to have a survival benefit over cisplatin plus etoposide, but confirmatory studies are needed. Patients with ED frequently relapse, and relapsed/refractory SCLC has a poor prognosis. The challenge remains to identify novel therapies and molecular targets to improve survival in SCLC.

KW - Carboplatin

KW - Chemoradiation

KW - Cisplatin

KW - Etoposide

KW - Prophylactic cranial irradiation

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=6944224365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6944224365&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2004.08.005

DO - 10.1016/j.critrevonc.2004.08.005

M3 - Review article

C2 - 15501076

AN - SCOPUS:6944224365

VL - 52

SP - 117

EP - 126

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -